期刊簡介 | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | ARCHIV DER PHARMAZIE LetPub Score 5.3
50 ratings
Rate
Reputation 6.4 Influence 4.0 Speed 7.1 | |||||||||||||||||||||
期刊簡稱 | ARCH PHARM | |||||||||||||||||||||
ISSN | 0365-6233 | |||||||||||||||||||||
E-ISSN | 1521-4184 | |||||||||||||||||||||
h-index | 54 | |||||||||||||||||||||
CiteScore |
| |||||||||||||||||||||
自引率 (2023-2024) | 4.70%自引率趨勢 | |||||||||||||||||||||
掲載範囲 |
| |||||||||||||||||||||
官方網站 | http://onlinelibrary.wiley.com/doi/10.1002/ardp.v344.10/issuetoc | |||||||||||||||||||||
在線稿件提交 | http://mc.manuscriptcentral.com/archpharm | |||||||||||||||||||||
開放訪問 | No | |||||||||||||||||||||
出版商 | Wiley-VCH Verlag | |||||||||||||||||||||
主題領域 | 医学 | |||||||||||||||||||||
出版國/地區 | GERMANY | |||||||||||||||||||||
發行頻率 | 月刊 | |||||||||||||||||||||
創刊年 | 1972 | |||||||||||||||||||||
每年文章數 | 160每年文章數趨勢 | |||||||||||||||||||||
黃金OA百分比 | 17.00% | |||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| |||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | |||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0365-6233%5BISSN%5D | |||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: About 3.0 month(s) | |||||||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | |||||||||||||||||||||
參考鏈接 |
| |||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[ARCHIV DER PHARMAZIE] 的評論 | 撰寫評論 |
作者: 义哥。。 領域: 医学 審稿時間: 2.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-12-04 13:31:51 評論於 The speed of journal review is acceptable, and both the editor and reviewers are very professional. It is a journal with good development prospects.(0) 讚! | 义哥。。 |
作者: 西风玉景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-22 08:54:56 評論於 How long is the review process expected to take?(0) 讚! | 西风玉景 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 19:48:40 評論於 Less often, more commonly in Chinese full pinyin(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 17:00:46 評論於 The first author of an SCI journal paper does not necessarily have to be the only one. There is no fixed standard for how many there can be. This is because different SCI journals have different policies on the number of corresponding authors. For SCI journals that only accept one corresponding author, if a paper has multiple corresponding authors, the first corresponding author will automatically be selected as the corresponding author. For SCI journals that allow two corresponding authors, two corresponding authors can be listed. Other requirements follow the same principle. In other words, the number of corresponding authors written by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contribution to the experimentation and article writing, identified as the first person listed in the author column. However, in collaborative efforts, it is common to have joint first authors. The number of joint first authors is not clearly defined, and it depends greatly on factors such as the workload, length of the paper, publication regulations, and institutional recognition. Typically, an SCI paper may have 2-4 first authors(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 上清雨真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 11:05:59 評論於 Can the author write their Chinese name?(0) 讚! | 上清雨真 |
作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 08:19:41 評論於 How many corresponding authors can there be at most? How many first authors can there be at most?(0) 讚! | 深渊兴业 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 15:01:17 評論於 ** It's frustrating that I received more than 2 points for my paper last year, but this year it's just over 1 point. Will it be even lower next year? Who would want to publish it?! **(0) 讚! | 凌霄高洁 |
作者: 五河怜莲 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-10-12 23:43:42 評論於 Review speed: 3.0 Experience Sharing: Can articles in the direction of traditional Chinese medicine monomer pharmacology be submitted?(0) 讚! | 五河怜莲 |
作者: 寒阴钢磊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-02-24 13:16:04 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Experience sharing: The review process takes 2-3 months with a total of 3 reviewers providing 12 comments(0) 讚! | 寒阴钢磊 |
作者: 匿名 領域: 医药科学 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2013-06-04 17:22:00 評論於 Recently, our lab group submitted a report, and we received reviews in about one month. When I submitted a different article a while ago, the review period was longer; the editor claimed that there weren’t enough available reviewers at the time. I actually only received reviews from one reviewer, and my manuscript was accepted quickly after revisions. (0) 讚! | 匿名 |
作者: 是曼青吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-06-04 15:31:22 評論於 Our submissions used to be around one month, but my review process took longer (sent a reminder once, and the editor replied that they couldn't find enough reviewers). Eventually, there was only one reviewer's comments, but after revisions it was quickly accepted. The editor was very efficient. Nowadays, there are increasing requirements for compound design, synthesis, activity data, etc., not only focusing on good activity, but also on comprehensive experimental data(0) 讚! | 是曼青吖 |
作者: 小尚文吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-05-08 09:45:08 評論於 In general, compound design and synthesis, as well as biological activity characterization, are two main aspects. Biological activity characterization may be relatively simple, but the activity requirements are quite strict. The standards for journals are getting higher and higher(0) 讚! | 小尚文吖 |
作者: 匿名 領域: 医药科学 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2012-05-08 08:33:00 評論於 generally requires two parts of compound design synthesis and biological activity characterization. The bioactivity characterization can be relatively simple, but the activity requirement is better.The journal requirements are getting higher and higher.(0) 讚! | 匿名 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us